Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
- PMID: 37104746
- DOI: 10.1200/JCO.22.02575
Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
Abstract
The role of neoadjuvant therapy is undergoing an historic shift in oncology. The emergence of potent immunostimulatory anticancer agents has transformed neoadjuvant therapy from a useful tool in minimizing surgical morbidity to a life-saving treatment with curative promise, led by research in the field of melanoma. Health practitioners have witnessed remarkable improvements in melanoma survival outcomes over the past decade, beginning with checkpoint immunotherapies and BRAF-targeted therapies in the advanced setting that were successfully adopted into the postsurgical adjuvant setting for high-risk resectable disease. Despite substantial reductions in postsurgical recurrence, high-risk resectable melanoma has remained a life-altering and potentially fatal disease. In recent years, data from preclinical models and early-phase clinical trials have pointed to the potential for greater clinical efficacy when checkpoint inhibitors are administered in the neoadjuvant rather than adjuvant setting. Early feasibility studies showed impressive pathologic response rates to neoadjuvant immunotherapy, which were associated with recurrence-free survival rates of over 90%. Recently, the randomized phase II SWOG S1801 trial (ClinicalTrials.gov identifier: NCT03698019) reported a 42% reduction in 2-year event-free survival risk with neoadjuvant versus adjuvant pembrolizumab in resectable stage IIIB-D/IV melanoma (72% v 49%; hazard ratio, 0.58; P = .004), establishing neoadjuvant single-agent immunotherapy as a new standard of care. A randomized phase III trial of neoadjuvant immunotherapy in resectable stage IIIB-D melanoma, NADINA (ClinicalTrials.gov identifier: NCT04949113), is ongoing, as are feasibility studies in high-risk stage II disease. With a swathe of clinical, quality-of-life, and economic benefits, neoadjuvant immunotherapy has the potential to redefine the contemporary management of resectable tumors.
Similar articles
-
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.N Engl J Med. 2023 Mar 2;388(9):813-823. doi: 10.1056/NEJMoa2211437. N Engl J Med. 2023. PMID: 36856617 Free PMC article. Clinical Trial.
-
Neoadjuvant immunotherapy for melanoma.J Surg Oncol. 2021 Mar;123(3):782-788. doi: 10.1002/jso.26229. Epub 2020 Oct 1. J Surg Oncol. 2021. PMID: 33002195 Free PMC article. Review.
-
Neoadjuvant Immunotherapy for Locally Advanced Melanoma.Curr Treat Options Oncol. 2020 Feb 5;21(2):10. doi: 10.1007/s11864-020-0700-z. Curr Treat Options Oncol. 2020. PMID: 32025932 Review.
-
Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.Future Oncol. 2019 Nov;15(32):3665-3674. doi: 10.2217/fon-2019-0433. Epub 2019 Sep 20. Future Oncol. 2019. PMID: 31538818
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18. Lancet Oncol. 2018. PMID: 29361468 Clinical Trial.
Cited by
-
Management of Localized Melanoma in the Anti-PD-1 Era.Curr Oncol Rep. 2024 Jun 6. doi: 10.1007/s11912-024-01556-z. Online ahead of print. Curr Oncol Rep. 2024. PMID: 38842606 Review.
-
Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma.Biomedicines. 2024 Mar 17;12(3):669. doi: 10.3390/biomedicines12030669. Biomedicines. 2024. PMID: 38540282 Free PMC article. Review.
-
Head and Neck Mucosal Melanoma: Where Are We Now?Curr Oncol Rep. 2024 Apr;26(4):421-425. doi: 10.1007/s11912-024-01513-w. Epub 2024 Mar 21. Curr Oncol Rep. 2024. PMID: 38512416 Review.
-
Molecular and functional anticancer effects of GLP/G9a inhibition by UNC0646 in MeWo melanoma cells.Heliyon. 2024 Feb 24;10(5):e27085. doi: 10.1016/j.heliyon.2024.e27085. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38434406 Free PMC article.
-
Multifunctional Near-Infrared Dye IR-817 Encapsulated in Albumin Nanoparticles for Enhanced Imaging and Photothermal Therapy in Melanoma.Int J Nanomedicine. 2023 Sep 4;18:4949-4967. doi: 10.2147/IJN.S425013. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37693889 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous